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BACKGROUND: Tumor necrosis factor (TNF)-a and inter-
leukin (IL)-1b are pro-inflammatory cytokines, caus-
ing myocardial dysfunction and a negative inotropic
effect. The drugs used to treat heart failure affect the
production  of  cytokines.  Digoxin,  on  which  this
study  was  focused,  is  one  of  the  drugs  for  the
treatment of heart failure.
Aim: The present study was designed to examine the
early effects of high doses of digoxin on the produc-
tion of cytokines in healthy dogs.
Methods: Digoxin was given parenterally to dogs at
0.15mg/kg. IL-1b and TNF-a production and levels of
digoxin in the serum were measured 0, 12, 24, 48, and
72h following administration of digoxin.
Results: As the levels of serum digoxin taken at 12, 24,
48,  and  72h  of  administration  were  considered
significantly high compared with preceding values (p
< 0.001), no notable change in serum IL-1b and TNF-a
levels was observed.
Conclusions: These results suggest that high doses of
digoxin do not cause a significant cytokine produc-
tion in heart muscle in the early phase.
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Introduction
Tumor necrosis factor (TNF)-a and interleukin (IL)-1b
are pro-inflammatory cytokines, causing  myocardial
dysfunction and a negative inotropic effect. The drugs
used  to treat heart failure  affect  the  production  of
cytokines. Digoxin, on which this study was focused,
is one of the drugs for the treatment of heart failure.1,2
Tumor  necrosis  factor  (cachectin)  is  a  pluripotent
cytokine, produced primarily by monocytes, that has
been  shown  experimentally  to  cause  fever  and
hypotension. Elevated circulating levels of TNF have
been noted in patients with a variety of neoplastic,
infectious, and collagen vascular disorders, many of
which are characterized by  severe weight loss  and
anorexia.3
In normal doses, digoxin has a positive effect on
heart  function  via  inhibition  of  sodium/potassium
ATPase or indirectly via the sympathicus nerve and
kidneys.  Digoxin  is  one  of  the  most  commonly
prescribed drugs  for  the treatment of heart failure,
and efficacy of digoxin in patients with heart failure
and atrial fibrillation is clear. However, this efficacy in
patients with heart failure and sinus rhythm has not
established.  Digoxin  has  no  significant  effect  on
mortality. Several recent short-term, randomized trials
indicated  that  withdrawing  digoxin  worsens  func-
tional status, exercise capacity, and the left ventricular
ejection fraction  in  patients  with  heart failure,  but
there is uncertainty about its efficacy and safety.4,5
We  hypothesized  that  negative  effects  by  high
doses of digoxin could be achieved by the release of
cytokines. This study  was designed  to  examine the
early effects of high doses of digoxin on the produc-
tion of cytokines in healthy dogs.
Materials and methods
Healthy  dogs  were  used for  the present  study. Ten
dogs  were  included  in  the  study.  The  study  was
approved by an internal ethical review board. Digoxin
was given parenterally at 0.15mg/kg, which is five-
fold  higher  than  the  usual  therapeutic  dose.  It  is
difficult  to  compare  dosages  in  different  animal
species; however, on the basis of the body surface
area, a given  dosage in  dogs is  comparable  with a
dosage  about  four-fold  lower  in  humans.  Thus,  a
dosage of 0.03mg/kg of digoxin in dogs is equivalent
to  0.008mg/kg  in  humans,  which  is  a  therapeutic
dose.2 None of  these  dogs  died. A total of 5ml  of
venous blood was drawn from each dog at 12, 24, 48,
and 72h following administration of digoxin. Blood
samples were was then centrifuged at 2000rpm for
10min in a refrigerated centrifuge to separate serum
samples from the cells. Serum samples were stored at
–70°C in  plastic  tubes  until  the analysis. IL-1b and
TNF-a production and levels of digoxin in the serum
samples were measured.
Serum digoxin, IL-1b and  TNF-awas measured using
commercial  kits,  which  are  a  solid-phase,  two-site
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Mediators of Inflammation, 11, 261–263 (2002)chemiluminescent  immunometric  assay  (Immullite;
DPC, Los Angeles, USA). Performance data for digoxin,
IL-1b and TNF-a, respectively, are as follows: calibra-
tion ranges, 0.5–8ng/ml, up to 1000pg/ml, and up to
1000pg/ml; analytical sensitivities, 0.1ng/ml, 1.5pg/
ml, and 1.7pg/ml; intra-assay coefficients of variation,
4.4%  at  a  concentration  of  1.6ng/ml,  2.8%  at  a
concentration of 39pg/ml, and 3.5% at a concentration
of 34pg/ml; inter-assay coefficients of variation, 9.4%
at a concentration of 1.6ng/ml, 7.7% at a concentra-
tion of 13pg/ml, and 6.5% at a concentration of 17pg/
ml; linearities, 94% at a dilution of 2 in 5, 95% at a
dilution of 4 in 8, and 90% at a dilution of 4 in 8; and
recoveries, average 109%, 102%, and 99%.
The  obtained  data  were  analyzed  by Wilcoxon’s
rank sum tests.
Results
Digoxin, IL-1b and TNF-a values obtained before and
at 12, 24, 48, and 72h following the administration of
digoxin are presented in Table 1.
As the levels of serum digoxin observed at 12, 24,
48,  and  72h  of  administration  were  considered
significantly high compared with preceding values (p
< 0.001), no notable change in serum IL-1b and TNF-a
levels was observed.
Discussion
In  previous studies, it  was  reported that IL-1b and
TNF-a levels  were increased in  patients  with  heart
failure. In the present study, we planned to investigate
the effect of high dose digoxin on IL-1b and TNF-a
levels in healthy subjects without any previous heart
failure, thereby using healthy dogs.
Each cytokine that shows various features is synthe-
sized  by  special  cell  types  to  be  a  response  to  a
specific  stimulus.  TNF  and  IL-1  are  mediators  of
natural immunity and they are synthesized by mono-
nuclear phagocytes.6
Cytokines  are  now  being  considered  important
factors in  the pathogenesis and pathophysiology of
heart failure. High levels of circulating cytokines have
been  reported  in  patients  with  heart  failure,  and
various  cytokines  have  been  shown  to  depress
myocardial  contractility  in  vitro and  in  vivo.1,7
Although  the  effect  of  IL-1  on  cardiac  function
remains controversial, it has been shown to decrease
cardiac contractility.8 More recently, IL-1b has been
found to cause myocyte hypertrophy associated with
the induction of fetal genes.9Another recent study has
reported that the chronic infusion  of TNF-a in rats
produces left ventricular contractile dysfunction and
dilatation.10 Transgenic  overexpression  of TNF-a in
the heart, using the cardiac-specific a-myosin heavy
chain  promoter,  has  just  been  reported  to  cause
systolic  dysfunction,  myocarditis,  ventricular  dilata-
tion,  and  the  development  of  heart  failure.11 Fur-
thermore, another transgenic line  expressing  lower
levels of cardiac  TNF-a caused dilated cardiomyopathy
without  prominent  inflammation.12 Thus,  available
data pertaining to cardiac transgenic overexpression
of TNF-a point to a direct relation between cytokine
concentrations and inflammatory response or mortal-
ity.13 TNF-a is  a  pro-inflammatory  cytokine  that
produces left ventricular dysfunction and a negative
inotropic effect in cardiac tissue when it is overex-
pressed  in  human  subjects.  Previous  studies  have
shown that levels of circulating TNF-a are elevated in
patients with advanced congestive heart failure, and
especially in those with cardiac cachexia.14
In the present study, in the result of administration
of a five-fold higher dose of digoxin, no increase in IL-
1b and  TNF-a levels  was  observed  within  72h.
Matsumori et al.2 showed that digoxin increased the
levels of  cytokines IL-1b, IL-6 and TNF-a in  cardiac
muscle of mice with viral myocarditis. But it is not
certain that this increase was solely due to digoxin
other than myocarditis and cardiac heart failure.
In another study conducted by Matsumori et al.,15
they found that the cardiac glycoside ouabain induces
the  production  of  IL-1b,  IL-6  and TNF-a in  human
peripheral blood mononuclear cells. Ouabain induced
mRNA of these cytokines, and the induction appeared
to  be  at  the  transcriptional  level. When  peripheral
blood mononuclear cells were stimulated with lipopo-
lysaccharide, however, ouabain suppressed the pro-
duction of IL-6 and TNF-a. Thus, cardiac glycosides
may be considered to have different effects on the
production of cytokines among those with and those
without immune activation.2
There may be various reasons for not observing any
notable changes in IL-1b and TNF-a levels in our study
when used high doses of digoxin. First, we used five
times as much digoxin as a normal therapeutic dose.
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Table 1. The values of digoxin, IL-1b and TNF-a obtained before and after administration of digoxin
0h (control) 12h 24h 48h 72h
Digoxin (ng/ml) 0.8 ± 0.14 12.0 ± 1.29* 7.8 ± 0.53* 3.7 ± 0.22* 3.0 ± 0.31*
IL-1b (pg/ml) 0.9 ± 0.35 1.1 ± 0.11 0.9 ± 0.13 0.9 ± 0.19 0.4 ± 0.10
TNF-a (pg/ml) 3.4 ± 0.64 4.0 ± 0.50 3.1 ± 0.45 3.2 ± 0.44 3.3 ± 0.47
*p < 0.001.This may have caused us to not observe any notable
results in the present study, but we think that if much
higher doses of digoxin had been used in this study,
much  more  notable  results  would  have  been
observed. Second, the present study was performed
only on healthy dogs. The effect of digoxin may of
course be different both in healthy dogs and in dogs
with heart failure. In fact, Matsumori et al.2 showed
that high doses of digoxin increased the serum IL-1b
and TNF-a levels in mice with heart failure developed
by viral myocarditis.
In the present study, serum TNF-a and IL-1b levels
were no different from those of the controls. These
results may suggest that high-dose digoxin might not
causes  a  significant  cytokine  production  in  early
phase.  But  our  results  need  to  be  supported  with
further  studies  with  longer  or  different  doses  of
digoxin treatment.
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